831-P: Tocilizumab Is Effective in Reducing Inflammation in T2D–COVID-Organ-on-a-Chip Model

The COVID-pandemic has contributed to more than 5 million deaths worldwide in the last two years. Co-morbid conditions such as Type 2 Diabetes (T2D) , HTN, obesity, and CKD have been associated with increased mortality with COVID-19. In a large meta-analysis, the relative risk of mortality was 1.54...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Diabetes (New York, N.Y.) N.Y.), 2022-06, Vol.71 (Supplement_1)
Hauptverfasser:	NEGI, VINNY, GAVLOCK, DILLON, LEE, JEONGKYUNG, SHUN, TONGYING, GOUGH, ALBERT, MIEDEL, MARK T., TAYLOR, D. LANSING L., YECHOOR, VIJAY
Format:	Artikel
Sprache:	eng
Schlagworte:	Animal models Biochips Clinical trials Coronaviruses COVID-19 Diabetes Diabetes mellitus (non-insulin dependent) Drug screening Endothelial cells Fatty acids Glucagon Hepatocytes Inflammation Insulin Interleukin 6 Kupffer cells Liver Macrophages Metabolic syndrome Monoclonal antibodies Morbidity Mortality Pathophysiology Patients Proteins Severe acute respiratory syndrome coronavirus 2
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!